Michael Barbella, Managing Editor04.02.24
OssDsign AB has been awarded a new three-year group purchasing (GPO) agreement for bone and bone substitute implantable products with Premier Inc., a U.S. healthcare improvement company uniting approximately 4,350 U.S. hospitals and health systems and more than 300,000 other providers and organizations.
Effective July 1, the agreement allows Premier members to take advantage of special pricing and terms pre-negotiated by Premier for OssDsign’s nanosynthetic bone graft, OssDsign Catalyst.
“We are pleased to have been awarded a long-term agreement with Premier for our synthetic bone graft. It is a clear recognition of our market offering, and opens up a large, valuable network providing many more hospitals and patients access to OssDsign Catalyst,” OssDsign CEO Morten Henneveld said.
OssDsign Catalyst is a nanosynthetic bone graft that stimulates healthy bone tissue formation in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure that is resorbed and replaced by new, healthy bone tissue. Twelve-month clinical study results have shown a 93% spinal fusion rate as well as improvements in quality of life and pain after OssDsign Catalyst use in surgery.
OssDsign develops and provides next-generation orthobiologics products that support the body's own healing capabilities. The company has a strong presence in the U.S. market. OssDsign's share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
Effective July 1, the agreement allows Premier members to take advantage of special pricing and terms pre-negotiated by Premier for OssDsign’s nanosynthetic bone graft, OssDsign Catalyst.
“We are pleased to have been awarded a long-term agreement with Premier for our synthetic bone graft. It is a clear recognition of our market offering, and opens up a large, valuable network providing many more hospitals and patients access to OssDsign Catalyst,” OssDsign CEO Morten Henneveld said.
OssDsign Catalyst is a nanosynthetic bone graft that stimulates healthy bone tissue formation in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure that is resorbed and replaced by new, healthy bone tissue. Twelve-month clinical study results have shown a 93% spinal fusion rate as well as improvements in quality of life and pain after OssDsign Catalyst use in surgery.
OssDsign develops and provides next-generation orthobiologics products that support the body's own healing capabilities. The company has a strong presence in the U.S. market. OssDsign's share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.